ATG003

Thuốc Gốc

Small Molecule

ATG003, a novel anti-angiogenic drug candidate and a formulation of mecamylamine, is currently in clinical development for neovascular age-related macular degeneration.

Cơ Chế Tác Dụng : ATG003, a novel anti-angiogenic drug candidate and a formulation of mecamylamine, is currently in clinical development for neovascular age-related macular degeneration. ATG003 acts by inhibiting the angiogenic pathway mediated by the nicotinic acetylcholine receptors found on endothelial cells (EC-NAChR). Inhibiting this pathway also inhibits the synthesis and cellular responses mediated by growth factors such as VEGF and bFGF.

Chỉ Định : Investigated for use/treatment in macular degeneration.

Tài Liệu Tham Khảo Thêm

drugbank

http://www.drugbank.ca/drugs/DB05069

Bạn thấy hài lòng ?

Bạn chưa hài lòng ?

... loading